Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lafutidine
- Development stage
- Phase 4
- Lead developer
- UCB
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lafutidine is a second-generation histamine H2 receptor antagonist used to treat gastrointestinal disorders such as peptic ulcers and gastroesophageal reflux disease (GERD). It acts primarily by inhibiting gastric acid secretion through antagonism of the histamine H2 receptor. Additionally, lafutidine exhibits a multimodal mechanism of action: it activates calcitonin gene-related peptide, stimulates nitric oxide production and regulates gastric mucosal blood flow, increases somatostatin levels (further reducing acid secretion), promotes mucin generation in the stomach lining, inhibits neutrophil activation to prevent inflammation-induced injury, and blocks *Helicobacter pylori* attachment to gastric cells. Its gastroprotective effects are also attributed to promoting restitution of damaged mucosa via capsaicin-sensitive afferent nerves rather than direct epithelial protection[5][6][7].
- Brand names
- StogarLafaxidIldong Lafutidine
- Other names
- N-(4-(4-piperidinylmethyl)pyridyl-2-oxy)-(Z)-butenyl-2-(furfurylsulfinyl)acetamideN-(4-(4-piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide
02
Targets
HRH2 (Histamine H2 Receptor)SST (Somatostatin)
Beyond the preview
Go deeper on lafutidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lafutidine.